Effect of everolimus on renal function in patients with tuberous sclerosis complex: evidence from EXIST-1 and EXIST-2

BACKGROUND: A reduction in renal angiomyolipoma volume observed with everolimus (EVE) treatment in patients with tuberous sclerosis complex (TSC) has been postulated to translate to clinical benefit by reducing the risk of renal hemorrhage and chronic renal failure. METHODS: The long-term effects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Bissler, John J, Budde, Klemens, Sauter, Matthias, Franz, David N, Zonnenberg, Bernard A, Frost, Michael D, Belousova, Elena, Berkowitz, Noah, Ridolfi, Antonia, Christopher Kingswood, J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545468/
https://www.ncbi.nlm.nih.gov/pubmed/30053159
http://dx.doi.org/10.1093/ndt/gfy132

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6545468/
https://www.ncbi.nlm.nih.gov/pubmed/30053159
http://dx.doi.org/10.1093/ndt/gfy132

Ejemplares similares